GlassScriptPhysician profile
Matthew T Greene
NPI 1871608943
$102,235.74
in general payments reported to CMS, 2019-2025
23 companies · $929 in 2025
The $929 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $1,575 · 2021: $34K · 2022: $27K · 2023: $1,390 · 2024: $745 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Entertainment: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.45 |
| Entertainment | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $95,835.78 | 2019-2025 | Precision 1, Precision7, Total30 |
| Coopervision INC. | $1,717.27 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Paragon Crt |
| Sun Pharmaceutical Industries INC. | $1,124.78 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $735.23 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $651.84 | 2019-2025 | Acuvue |
| Glaukos Corporation | $322.24 | 2021-2024 | Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $262.83 | 2019-2021 | |
| Allergan, INC. | $257.26 | 2019-2021 | |
| Oyster Point Pharma, INC. | $186.33 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $172.92 | 2022-2025 | |
| Optos, INC. | $165.66 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $153.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $138.49 | 2021 | |
| Sight Sciences, INC. | $124.95 | 2019 | |
| Rxsight INC | $122.79 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $67.32 | 2020 | |
| Bausch & Lomb Americas INC. | $44.32 | 2022-2024 | Xiidra, Miebo |
| Lombart Brothers, INC. | $35.82 | 2024 | Opd-III |
| Dompe US, INC. | $32.68 | 2024 | Oxervate |
| Genzyme Corporation | $29.20 | 2024 | |
| Synergeyes, INC. | $27.28 | 2021 | |
| Kala Pharmaceuticals, INC. | $16.42 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.